ToPCourT protocol: a phase II trial of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced/unresectable or metastatic triple-negative breast cancer
{{output}}
Triple-negative breast cancer (TNBC) is a clinically aggressive and difficult to treat malignancy. It has a poorer prognosis when compared to the hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-positive subtypes. Due to ... ...
